» Articles » PMID: 38893234

Phospholipid Acyltransferases: Characterization and Involvement of the Enzymes in Metabolic and Cancer Diseases

Overview
Journal Cancers (Basel)
Publisher MDPI
Specialty Oncology
Date 2024 Jun 19
PMID 38893234
Authors
Affiliations
Soon will be listed here.
Abstract

This review delves into the enzymatic processes governing the initial stages of glycerophospholipid (phosphatidylcholine, phosphatidylethanolamine, and phosphatidylserine) and triacylglycerol synthesis. The key enzymes under scrutiny include GPAT and AGPAT. Additionally, as most AGPATs exhibit LPLAT activity, enzymes participating in the Lands cycle with similar functions are also covered. The review begins by discussing the properties of these enzymes, emphasizing their specificity in enzymatic reactions, notably the incorporation of polyunsaturated fatty acids (PUFAs) such as arachidonic acid and docosahexaenoic acid (DHA) into phospholipids. The paper sheds light on the intricate involvement of these enzymes in various diseases, including obesity, insulin resistance, and cancer. To underscore the relevance of these enzymes in cancer processes, a bioinformatics analysis was conducted. The expression levels of the described enzymes were correlated with the overall survival of patients across 33 different types of cancer using the GEPIA portal. This review further explores the potential therapeutic implications of inhibiting these enzymes in the treatment of metabolic diseases and cancer. By elucidating the intricate enzymatic pathways involved in lipid synthesis and their impact on various pathological conditions, this paper contributes to a comprehensive understanding of these processes and their potential as therapeutic targets.

References
1.
Beigneux A, Vergnes L, Qiao X, Quatela S, Davis R, Watkins S . Agpat6--a novel lipid biosynthetic gene required for triacylglycerol production in mammary epithelium. J Lipid Res. 2006; 47(4):734-44. PMC: 3196597. DOI: 10.1194/jlr.M500556-JLR200. View

2.
Wang K, Wu Z, Si Y, Tang W, Xu X, Cheng Y . Identification of expression as a potential prognostic biomarker guiding treatment choice in acute myeloid leukemia. Oncol Lett. 2020; 21(2):105. PMC: 7751346. DOI: 10.3892/ol.2020.12366. View

3.
Zhang H, Xu K, Xiang Q, Zhao L, Tan B, Ju P . LPCAT1 functions as a novel prognostic molecular marker in hepatocellular carcinoma. Genes Dis. 2022; 9(1):151-164. PMC: 8720658. DOI: 10.1016/j.gendis.2020.07.007. View

4.
Li Z, Hu Y, Zheng H, Li M, Liu Y, Feng R . LPCAT1-mediated membrane phospholipid remodelling promotes ferroptosis evasion and tumour growth. Nat Cell Biol. 2024; 26(5):811-824. DOI: 10.1038/s41556-024-01405-y. View

5.
Shen L, Gu P, Qiu C, Ding W, Zhang L, Cao W . Lysophosphatidylcholine acyltransferase 1 promotes epithelial-mesenchymal transition of hepatocellular carcinoma via the Wnt/β-catenin signaling pathway. Ann Hepatol. 2022; 27(3):100680. DOI: 10.1016/j.aohep.2022.100680. View